当前位置：药药网 / 药品研发 / 美国药品上市后承诺数据库
Privigen, Immune Globulin Intravenous (Human), 10% Liquid
药品名称
Privigen, Immune Globulin Intravenous (Human), 10% Liquid
承诺描述
Deferred pediatric study under PREA for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) to improve neuromuscular disability and impairment and for maintenance therapy to prevent relapse in pediatric patients ages 2 to less than 17 years. The study will be a randomized study of single versus multiple Privigen dosing.
承诺状态描述
The study is ongoing.